NCT06826326
Neuroimaging of Escitalopram in Autism Spectrum Disorder
Enrolling by Invitation
PHASE2Ages 12–17InterventionalBasic scienceKathryn UnruhInvestigator-initiated
~5 participants
Updated 2026-02-18 on ClinicalTrials.gov
What's tested:Escitalopram 10mgPlacebo
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rewarded Antisaccade task
Measured over At Visit 2 (1 day to 1 month after Screening/Visit 1) and Visit 3 (5 days to 3 weeks after Visit 2)
Conditions
Where it's being run
1 sites across 1 statesKansas1
Study leadership
- Kathryn E Unruh, PhD · PRINCIPAL_INVESTIGATOR · University of Kansas
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Rewarded Antisaccade taskAt Visit 2 (1 day to 1 month after Screening/Visit 1) and Visit 3 (5 days to 3 weeks after Visit 2)
During the rewarded antisaccade task (R-ANTI), participants are instructed to look away from a peripheral target and to the mirror location in the opposite hemifield (antisaccade) and avoid looking toward the peripheral target (prosaccade). Two trial types are presented: reward and no-reward. Number of prosaccades is compared between reward and no-reward trial types.